Ikena Oncology, Inc.
(NASDAQ : IKNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.66%245.101.5%$887.83m
MRNAModerna, Inc. 0.73%156.670.0%$858.81m
VRTXVertex Pharmaceuticals, Inc. 0.93%291.671.9%$513.59m
GILDGilead Sciences, Inc. -0.18%62.231.0%$476.46m
NVAXNovavax, Inc. -2.48%62.7075.7%$457.30m
REGNRegeneron Pharmaceuticals, Inc. -0.87%591.362.6%$448.85m
ILMNIllumina, Inc. 1.22%195.373.3%$361.99m
SNSSSunesis Pharmaceuticals, Inc. 0.53%3.800.7%$265.63m
BIIBBiogen, Inc. 0.93%214.571.8%$247.46m
BNTXBioNTech SE -1.71%158.280.0%$212.28m
CRSPCRISPR Therapeutics AG 0.94%71.270.6%$194.34m
BMRNBioMarin Pharmaceutical, Inc. -0.12%86.264.2%$117.34m
AXSMAxsome Therapeutics, Inc. 2.70%42.321.8%$102.01m
EXASEXACT Sciences Corp. -1.64%43.6717.7%$100.83m
TECHBio-Techne Corp. -0.15%361.754.5%$95.97m

Company Profile

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.